We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.
|Bid||40.50 x 300|
|Ask||40.53 x 1900|
|Day's Range||40.14 - 40.35|
|52 Week Range||34.52 - 44.54|
|PE Ratio (TTM)||46.14|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||2.55 (6.29%)|
|1y Target Est||40.43|
As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.
GlaxoSmithKline (GSK) is set to release its 1Q18 earnings on April 25, 2018. The below chart shows the company’s revenues and earnings per share (or EPS) since 1Q17 and analysts’ estimates for 1Q18. Analysts estimate the company will post EPS of 24.21 pence on revenues of 7.2 billion pounds in 1Q18.
WALTHAM, Mass., April 19, 2018-- NeuroMetrix, Inc., today reported financial and business highlights for the quarter ended March 31, 2018.. The Company develops and markets novel therapies, based on neurostimulation ...
Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline (GSK.L), which the company hopes will help it keep its lead in respiratory medicine despite rising competition. Trelegy Ellipta was licensed for use last year and full results from a positive clinical trial were published on Wednesday in the New England Journal of Medicine (NEJM). Trelegy is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca (AZN.L) and Novartis (NOVN.S), and it showed benefits over other treatments in the study.
A significant reduction in the risk of on-treatment all-cause mortality was observed for both inhaled corticosteroid containing arms compared to Anoro. Dave Allen, Head, Respiratory Therapy Area R&D, GSK, said, “Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life. The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals.
Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition. Trelegy Ellipta was licensed for use last year and full results from a positive clinical trial were published on Wednesday in the New England Journal of Medicine (NEJM). Trelegy is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca and Novartis, and it showed benefits over other treatments in the study.
GlaxoSmithKline (GSK.L) signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's (ROG.S) Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.
|Downgrade||Bank of America : Buy to Neutral||10/26/2017|
|Downgrade||Citigroup : to Neutral||7/5/2017|
|Initiated||PiperJaffray : to Overweight||9/23/2016|
|Downgrade||Exane BNP Paribas : to Underperform||9/14/2016|
|Upgrade||Jefferies : to Buy||7/14/2016|
|Initiated||Cantor Fitzgerald : to Hold||2/26/2016|
Industry : Drug Manufacturers - Major
Full Time Employees : 98,462
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.